NCT02737371 - Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

May 22, 2017

Study Completion Date

May 22, 2017

Conditions

Invasive Aspergillosis

Interventions

DRUG

F901318 Dose level A oral

Adverse events days 1-10

DRUG

Placebo dose level A oral

Placebo adverse events days 1-10

DRUG

F901318 Dose level B oral

F901318 adverse events days 1-10

DRUG

Placebo dose level B oral

Placebo adverse events days 1-10

DRUG

F901318 Dose level C oral

F901318 adverse events days 1-10

DRUG

Placebo Dose level C oral

Placebo adverse events days 1-10

Trial Locations (1)

Simbec Research Ltd, Merthyr Tydfil